Phase 2 N=9 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
Hippel-Lindau Disease · Kidney Cancer
Primary: Number of Participants With a Renal Tumor Response — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=214 A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma
Melanoma
Primary: Progression-free Survival — 4.2; 5.6 months
Phase 2 N=49 Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy — 500; 20; 500; 75 milligrams per square meter (mg/m^2)
Phase 2 N=67 Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
HIV Infection · Hepatitis C Infection
Primary: Percentage of Participants With Complete Early Virologic Response (cEVR) — 38.8 percentage of participants
Phase 2 N=26 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Lung Cancer · Metastatic Cancer
Primary: Number of Patients With Intracranial Response — 3 participants
Phase 2 N=30 Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) — 125.5 days
Phase 2 N=76 Safety and Efficacy Study of CF101 to Treat Psoriasis
Plaque Psoriasis
Primary: Change From Baseline (CFB) in Psoriasis Area and Severity Index (PASI) Score — -0.67; -8.8; -4.1; -2.7 Scores on a scale — p=0.031
Phase 2 N=6 Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone
Type 1 Diabetes
Primary: Effectiveness of Closed Loop Diabetes Control — 136.9; 149.5 mg/dl
Phase 2 N=55 Cardiac Electrophysiological Study
Atrial Flutter
Primary: LAERP (Left Atrial Effective Refractory Period (ie, the Longest S1-S2 Interval That Fails to Result in Atrial Depolarisation)) — 11; 43; 55; 50 ms
Phase 2 N=949 Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation
Nonvalvular Atrial Fibrillation
Primary: Bleeding Events — 18; 8; 22; 17 Participants
Phase 2 N=263 A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
Macular Edema
Primary: Percent of Patients Who Developed Macular Edema (ME) Within 90 Days Following Cataract Surgery — 3; 17 Percentage of patients
Phase 2 N=5 MGA031, Sirolimus and Tacrolimus in Islet Transplantation
Type 1 Diabetes Mellitus · Hypoglycemia
Primary: Subjects With Full Islet Function. — 3 Participants
Phase 2 N=211 AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
Ovarian Neoplasms · Ovarian Cancer
Primary: Objective Response Rate as Evaluated by Response Evaluation Criteria In Solid Tumors ( RECIST) — 47; 45 Participants
Phase 2 N=53 Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 5.6 Months
Phase 2 N=118 Internet-based Treatment for Chronic Insomnia
Insomnia · Insomnia Disorder
Primary: Sleep Quality — 1.77; 2.18 0-4 scale of sleep quality